Shionogi, Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1919-01-01

Employees: -

Market Cap: $13.1B

Website: https://www.shionogi.com/jp/ja/

Clinical Trials

A Study of S-740792 in Healthy Adult Study Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: S-740792
Drug: Placebo
Drug: Midazolam

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-16

Lead Sponsor: Shionogi

Target Recruit Count: 116

Registration Number: NCT06724978

Locations: 🇺🇸
Fortrea Clinical Research Unit, Inc., Daytona Beach, Florida, United States

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Phase 2

Not yet recruiting

Conditions: Jordan's Syndrome
PPP2R5D Neurodevelopmental Disorder

Interventions: Drug: BPN14770
Drug: Placebo

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Shionogi

Target Recruit Count: 30

Registration Number: NCT06717438

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: S-337395
Drug: Placebo

First Posted Date: 2024-02-21

Last Posted Date: 2024-07-10

Lead Sponsor: Shionogi

Target Recruit Count: 50

Registration Number: NCT06270511

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

Phase 1

Completed

Conditions: Obesity
Healthy Volunteers

Interventions: Drug: S309309
Drug: Itraconazole

First Posted Date: 2023-10-30

Last Posted Date: 2024-02-29

Lead Sponsor: Shionogi

Target Recruit Count: 14

Registration Number: NCT06106334

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Phase 2

Recruiting

Conditions: Gram-Negative Bacterial Infections

Interventions: Drug: Cefiderocol
Drug: Standard of Care

First Posted Date: 2023-10-17

Last Posted Date: 2024-06-05

Lead Sponsor: Shionogi

Target Recruit Count: 40

Registration Number: NCT06086626

Locations: 🇨🇳
Chang Gung Memorial Hospital, Linkou Department of Pediatrics, Taoyuan City, Taiwan
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇿🇦
Tygerberg Hospital, Cape Town, Western Cape, South Africa

and more 1 locations

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Phase 2

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Biological: Redasemtide
Drug: Placebo

First Posted Date: 2023-07-20

Last Posted Date: 2024-10-01

Lead Sponsor: Shionogi

Target Recruit Count: 627

Registration Number: NCT05953480

Locations: 🇦🇺
Monash Health, Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇨🇿
Fakultni Nemocnice Olomouc, Olomouc, Olomoucký Kraj, Czechia

and more 162 locations

Safety and Efficacy Study of S-309309 in Obese Adults

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: S-309309
Drug: Placebo

First Posted Date: 2023-06-29

Last Posted Date: 2024-06-28

Lead Sponsor: Shionogi

Target Recruit Count: 365

Registration Number: NCT05925114

Locations: 🇺🇸
Catalina Research Institute, Montclair, California, United States
🇺🇸
L MARC Research Center, Louisville, Kentucky, United States
🇺🇸
Be Well Clinical Studies LLC, Lincoln, Nebraska, United States

and more 45 locations

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Phase 3

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Drug: Placebo
Drug: S-217622

First Posted Date: 2023-06-09

Last Posted Date: 2024-11-26

Lead Sponsor: Shionogi

Target Recruit Count: 2387

Registration Number: NCT05897541

Locations: 🇺🇸
MedQuest Translational Sciences, Miami Lakes, Florida, United States
🇺🇸
LCC Medical Research - Miami - ClinEdge - PPDS, Miami, Florida, United States
🇺🇸
CCM Clinical Reseearch Group, Miami, Florida, United States

and more 95 locations

Use of Cefiderocol in the Management of Gram-Negative Infections

Completed

Conditions: Gram-Negative Infection

Interventions: Drug: Cefiderocol

First Posted Date: 2023-03-29

Last Posted Date: 2023-06-26

Lead Sponsor: Shionogi

Target Recruit Count: 314

Registration Number: NCT05789199

Locations: 🇪🇸
Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸
Hospital Universitario Torrecardenas, Almeria, Almeria, Spain
🇪🇸
Hospital General Universitario Gregorio Marañón, Madrid, Spain

and more 52 locations

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Phase 1

Recruiting

Conditions: Opioid-Induced Constipation (OIC)

Interventions: Drug: Naldemedine

First Posted Date: 2022-10-20

Last Posted Date: 2024-10-14

Lead Sponsor: Shionogi

Target Recruit Count: 24

Registration Number: NCT05588323

Locations: 🇫🇷
Chu de Caen, Caen, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy